Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas

P. Casali, U. Pastorino, A. Azzarelli, R. Bertulli, P. Zucchinelli, L. Devizzi, A. Santoro

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults. Given in combination at full doses, with or without dacarbazine, these agents have induced higher response rates than were obtained with single-agent therapy. Because they involve considerable myelotoxicity, however, full-dose regimens should be reserved for patients with good performance status and without potential septic foci. Obviously, higher response rates do not automatically translate into improved survival. In soft tissue sarcomas, full-dose polychemotherapy will most probably provide a survival benefit only in selected patients in whom surgery can be performed in combination with chemotherapy. Prospective trials in such patients, although difficult to carry out, would be highly desirable. The information they would provide might help the clinician tail or treatment in a more rational way and improve chances of cure or long-term survival in at least some patient subgroups.

Original languageEnglish
JournalCancer Chemotherapy and Pharmacology
Volume31
Issue numberSUPPL. 2
Publication statusPublished - 1993

Fingerprint

Ifosfamide
Anthracyclines
Sarcoma
Tissue
Dacarbazine
Chemotherapy
Combination Drug Therapy
Doxorubicin
Surgery
Survival
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. / Casali, P.; Pastorino, U.; Azzarelli, A.; Bertulli, R.; Zucchinelli, P.; Devizzi, L.; Santoro, A.

In: Cancer Chemotherapy and Pharmacology, Vol. 31, No. SUPPL. 2, 1993.

Research output: Contribution to journalArticle

@article{ee1712688ae542908f94d67ed57738b0,
title = "Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas",
abstract = "Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults. Given in combination at full doses, with or without dacarbazine, these agents have induced higher response rates than were obtained with single-agent therapy. Because they involve considerable myelotoxicity, however, full-dose regimens should be reserved for patients with good performance status and without potential septic foci. Obviously, higher response rates do not automatically translate into improved survival. In soft tissue sarcomas, full-dose polychemotherapy will most probably provide a survival benefit only in selected patients in whom surgery can be performed in combination with chemotherapy. Prospective trials in such patients, although difficult to carry out, would be highly desirable. The information they would provide might help the clinician tail or treatment in a more rational way and improve chances of cure or long-term survival in at least some patient subgroups.",
author = "P. Casali and U. Pastorino and A. Azzarelli and R. Bertulli and P. Zucchinelli and L. Devizzi and A. Santoro",
year = "1993",
language = "English",
volume = "31",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas

AU - Casali, P.

AU - Pastorino, U.

AU - Azzarelli, A.

AU - Bertulli, R.

AU - Zucchinelli, P.

AU - Devizzi, L.

AU - Santoro, A.

PY - 1993

Y1 - 1993

N2 - Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults. Given in combination at full doses, with or without dacarbazine, these agents have induced higher response rates than were obtained with single-agent therapy. Because they involve considerable myelotoxicity, however, full-dose regimens should be reserved for patients with good performance status and without potential septic foci. Obviously, higher response rates do not automatically translate into improved survival. In soft tissue sarcomas, full-dose polychemotherapy will most probably provide a survival benefit only in selected patients in whom surgery can be performed in combination with chemotherapy. Prospective trials in such patients, although difficult to carry out, would be highly desirable. The information they would provide might help the clinician tail or treatment in a more rational way and improve chances of cure or long-term survival in at least some patient subgroups.

AB - Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults. Given in combination at full doses, with or without dacarbazine, these agents have induced higher response rates than were obtained with single-agent therapy. Because they involve considerable myelotoxicity, however, full-dose regimens should be reserved for patients with good performance status and without potential septic foci. Obviously, higher response rates do not automatically translate into improved survival. In soft tissue sarcomas, full-dose polychemotherapy will most probably provide a survival benefit only in selected patients in whom surgery can be performed in combination with chemotherapy. Prospective trials in such patients, although difficult to carry out, would be highly desirable. The information they would provide might help the clinician tail or treatment in a more rational way and improve chances of cure or long-term survival in at least some patient subgroups.

UR - http://www.scopus.com/inward/record.url?scp=0027404526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027404526&partnerID=8YFLogxK

M3 - Article

VL - 31

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - SUPPL. 2

ER -